This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

Despite the recent attention to the potential of developing and using gene therapy to treat several diseases, the therapy was ...

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...

About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced ...

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...